Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study
Low-Dose Trazodone for Delirium in Patients with Cancer Who Received Specialist Palliative Care: A Multicenter Prospective Study
复制标题
DOI：
10.1089/jpm.2020.0610
复制
发表时间：
2021-02-11
影响因子：
2.8
通讯作者：
Iwase, Satoru
中科院分区：
文献类型：
--
作者：
Maeda, Isseki;Inoue, Shinichiro;Iwase, Satoru
背景资料：曲唑酮对接受姑息治疗患者谵妄的临床有效性尚不清楚。目的：检查曲唑酮对谵妄的安全性和有效性。设计：多中心前瞻性观察研究的次要分析。设置/受试者：该设置涉及日本的9个心理肿瘤咨询服务和14个住院姑息治疗单位。测量：测量涉及谵妄评定量表（DRS）修订-98的有效性和CTCAE（不良事件通用术语标准）第4版的安全性assessment.Results：38例患者入组了这项研究。平均年龄为75岁。观察3天后，（11.6 ± 5.3至8.7 ± 6.5 [差异-2.9，95%置信区间-5.3至-0.5，p = 0.02]）;睡眠-觉醒周期紊乱（p = 0.047）、情感不稳定（p < 0.001）和运动性激动分量表（p < 0.001）显著降低。最常见的不良事件是嗜睡（n = 9）。结论：低剂量曲唑酮治疗一般是安全的，可能是有效的，在减少谵妄的严重程度。
Background: Clinical usefulness of trazodone for delirium in patients receiving palliative care is unclear.Objectives: To examine the safety and effectiveness of trazodone for delirium.Design: A secondary analysis of a multicenter prospective observational study.Setting/Subjects: The setting involves nine psycho-oncology consultation services and 14 inpatient palliative care units in Japan.Measurements: The measurement involves the Delirium Rating Scale (DRS) Revised-98 for effectiveness and the CTCAE (Common Terminology Criteria for Adverse Events) version 4 for safety assessments.Results: Thirty-eight patients enrolled the study. Mean age was 75 years. After three-day observation, the DRS total score (11.6 +/- 5.3 to 8.7 +/- 6.5 [difference -2.9, 95% confidence interval -5.3 to -0.5, p = 0.02]); sleep-wake cycle disturbance (p = 0.047), lability of affect (p < 0.001), and motor agitation subscales (p < 0.001) were significantly decreased. The most frequent adverse event was somnolence (n = 9).Conclusions: Low-dose trazodone treatment was generally safe and may be effective in reducing delirium severity.